Then, based on the OS information, we performed subgroup analyses of prognosis, which demonstrated that the survival rates of patients with cutaneous melanoma with higher CDCA3 expression was poor in the T stages I–II, N0, M0, race of white, age > 60, female, Breslow depth< 3 and pathologic stage I−II subgroups (Supplement Figure 5D-K). The gene discussed is CDCA3; the disease is cutaneous melanoma.